Attachment II - Page 20 
20 
C. A one-page scientific abstract of the gene therapy protocol. 
D. A one-page description of the preposed experiment in nontechnical language. 
E. Curricula vitae for professional personnel. 
F. An indication of other federal agencies to which the protocol is 
being submitted for review. 
G. Any other material which you believe will aid in the review. 
IV. Reporting Requirements 
A. Serious adverse effects of treatment should be reported immediately 
bo both your local IRB and the NIH Office for Protection frem Research 
Risks, and a written report should be filed with both groups. A copy 
of the report should also be forwarded to the NIH Office of Recombinant 
Dt^ Activities (ORDA). 
B. Reports regarding the general progress of patients should be filed 
at six-month intervals with both your local IRB and ORDA. 
These twice-yearly reports should continue for a sufficient period of 
time to allcw observation of all major effects (at least three to 
five years). In the event of a patient's death, the autopsy report 
should be submitted to the IRB and ORDA. 
[439] 
